Overview

Useful For
Aiding in the diagnosis of neuroinvasive Lyme disease or neuroborreliosis due to *Borrelia* species associated with Lyme disease (eg, *B. burgdorferi, B. garinii, B. afzelii*)

Highlights
This test should be ordered in patients with suspected neuroinvasive Lyme disease.

Although a small percentage of patients with neuroinvasive Lyme disease may be seronegative, it is recommended that all patients test by the Lyme Antibody Index assay also have standard 2-tiered testing for Lyme disease performed on serum.

This test compares the level of IgG antibodies to Lyme disease-causing *Borrelia* species in spinal fluid (CSF) and serum. The level of anti-*Borrelia* species IgG is normalized to total IgG and albumin in CSF and serum.

This test can help identify whether the presence of IgG to *Borrelia* species in the CSF is due to true intrathecal antibody synthesis, suggesting neuroinvasive Lyme disease, versus antibody presence due to passive diffusion through the blood-brain barrier or possibly, due to blood contamination of the CSF as a result of a traumatic lumbar puncture.

Profile Information

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Reporting Name</th>
<th>Available Separately</th>
<th>Always Performed</th>
</tr>
</thead>
<tbody>
<tr>
<td>LNBAC</td>
<td>Lyme CNS Infection IgG</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Screen, CSF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LNBAS</td>
<td>Lyme CNS Infection IgG, S</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

Reflex Tests

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Reporting Name</th>
<th>Available Separately</th>
<th>Always Performed</th>
</tr>
</thead>
<tbody>
<tr>
<td>LNBAI</td>
<td>Lyme CNS Infection IgG, Ab Index</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

Testing Algorithm
This test begins with IgG screening of the spinal fluid (CSF) specimen. If the screen is negative, no additional testing will be performed.

If the screen is positive, the paired CSF and serum specimens will be used to establish the antibody index. In order to establish the antibody index, the paired serum and CSF samples (collected within 24 hours of each other) are tested on the same run using quantitative assays to determine levels for the following analytes:

1. Anti-*Borrelia* species IgG levels in CSF and serum
2. Total IgG in CSF and serum
3. Albumin in CSF and serum

These additional tests are necessary in order to normalize the level of anti-*Borrelia* antibodies to total IgG and albumin in the CSF and establish the antibody index ratio of anti-*Borrelia* antibodies in CSF-to-serum. This testing is performed at an additional charge.

The following algorithms are available in Special Instructions:

- Lyme Neuroborreliosis Diagnostic Algorithm
- Acute Tick-Bourne Disease Testing Algorithm
- Meningitis/Encephalitis Panel Algorithm

### Special Instructions

- Acute Tick-Bourne Disease Testing Algorithm
- Lyme Neuroborreliosis Diagnostic Algorithm
- Meningitis/Encephalitis Panel Algorithm

### Method Name

Enzyme-Linked Immunosorbent Assay (ELISA)

### NY State Available

Yes

### Specimen

#### Specimen Type

CSF 
Serum

#### Advisory Information

This test is preferred for diagnosis of neuroinvasive Lyme disease over testing of spinal fluid (CSF) by immunoblot for IgM and IgG class antibodies to *Borrelia* species associated with Lyme disease. This test is recommended because it can help distinguish true intrathecal synthesis of antibodies to Lyme disease in the CSF, indicating neuroinvasive infection, versus antibody presence due to passive diffusion through the blood-brain barrier or possibly, due to blood contamination of the CSF as a result of a traumatic lumbar puncture.

For Lyme testing on serum, order LYME / Lyme Disease Serology, Serum.

### Additional Testing Requirements

Although a small percentage of patients with neuroinvasive Lyme disease may be seronegative, it is recommended that all patients tested by this assay also have standard 2-tiered testing for Lyme disease performed (LYME / Lyme Disease Serology, Serum).

### Specimen Required

Both spinal fluid (CSF) and serum are required for this test. CSF and serum must be collected within 24 hours maximum of each other.

#### Specimen Type:

Spinal Fluid
Collection Container/Tube: Sterile vial

Specimen Volume: 1.5 mL

Collection Instructions:

1. A spinal fluid sample of 1.5 mL needs to be collected within 24 hours of the serum specimen, preferably at the same time.

2. Label vial as spinal fluid or CSF.

3. CSF aliquot should be from the second, third, or fourth CSF vial collected during the lumbar puncture. - Do not submit CSF from the first vial due to the possibility of blood contamination, which will cause specimen rejection.

4. Band specimens together.

Specimen Type: Serum

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Specimen Volume: 1.5 mL

Collection Instructions:

1. A serum sample of 1.5 mL needs to be collected within 24 hours of the spinal fluid specimen, preferably at the same time.

2. Label as serum.


Forms
If not ordering electronically, complete, print, and send a Microbiology Test Request (T244) with the specimen.

Specimen Minimum Volume
CSF: 1.2 mL
Serum: 1.2 mL

Reject Due To

<table>
<thead>
<tr>
<th>Gross hemolysis</th>
<th>Reject</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross lipemia</td>
<td>Reject</td>
</tr>
<tr>
<td>CSF</td>
<td>Contaminated with blood</td>
</tr>
</tbody>
</table>

Specimen Stability Information
Clinical and Interpretive

Clinical Information

Lyme disease is a multisystem and multistage tick-transmitted infection caused by spirochetal bacteria in the *Borrelia burgdorferi* sensu lato (Bbsl) complex. Nearly all human infections are caused by 3 Bbsl species; *B burgdorferi* sensu stricto (hereafter referred to as *B burgdorferi*) is the primary cause of Lyme disease in North America, while *B afzelii* and *B garinii* are the primary causes of Lyme disease in Europe and parts of Asia.

Lyme disease is the most commonly reported tick-borne infection in North America and Europe, causing an estimated 300,000 cases in the United States each year and 85,000 cases in Europe. The clinical features of Lyme disease are broad and may be confused with various immune and inflammatory disorders. The classic presenting sign of early localized Lyme disease caused by *B burgdorferi* is erythema migrans (EM), which occurs in approximately 80% of individuals. Other early signs and symptoms include malaise, headache, fever, lymphadenopathy, and myalgia. Arthritis, cardiac disease, and neurological disease may be later stage manifestations.

Neuroinvasive Lyme disease (NLD) can affect either the peripheral or central nervous system, with patients classically presenting with the triad of lymphocytic meningitis, cranial neuropathy (especially facial nerve palsy) and radiculoneuritis, which can affect the motor or sensory nerves, or both. These symptoms can occur in any combination or alone. Some patients may present with Bannwarth syndrome, which includes painful radiculoneuritis with variable motor weakness.

NLD should be considered in individuals presenting with appropriate symptoms who have had exposure to ticks in a Lyme endemic region of the United States, Europe or Asia. Patients meeting these criteria should be evaluated for the presence of anti-Bbsl antibodies in serum using the standard 2-tiered testing algorithm (LYME / Lyme Disease Serology, Serum) as recommended by the CDC. Briefly, the LYME test includes testing of serum specimens by an anti-Bbsl antibody ELISA, followed by supplemental testing of all reactive samples using an immunoblot or western blot for detection of IgM- and IgG-class antibodies to Bbsl. Notably, the majority of patients with NLD will be seropositive in serum. Therefore, it is recommended that all patients tested by this assay also have LYME / Lyme Disease Serology, Serum performed. Results from these assays, alongside appropriate exposure history and clinical presentation, may be used to establish a diagnosis of NLD.

Spinal fluid (CSF) should not be tested for the presence of antibodies to Bbsl using the current 2-tiered testing algorithm as there are no interpretive criteria for assessment of anti-Bbsl IgM and IgG immunoblot banding patterns in CSF. Additionally, while the presence of antibodies to Bbsl in CSF may be due to true intrathecal antibody synthesis, thus indicating central nervous system (CNS) infection, antibodies may alternatively be present as a result of passive diffusion through the blood-brain barrier or due to blood contamination of CSF during a traumatic lumbar puncture.

The Lyme CNS infection antibody index (AI) is performed as a reflex and quantitatively measures the level of anti-Bbsl antibodies in CSF and serum, ideally collected within 24 hours of each other, and normalizes those levels to

---

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Temperature</th>
<th>Time</th>
<th>Special Container</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSF</td>
<td>Refrigerated (preferred)</td>
<td>11 days</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Frozen</td>
<td>35 days</td>
<td></td>
</tr>
<tr>
<td>Serum</td>
<td>Refrigerated (preferred)</td>
<td>11 days</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Frozen</td>
<td>35 days</td>
<td></td>
</tr>
</tbody>
</table>
total IgG and albumin in both specimen sources. A positive Lyme CNS AI indicates true intrathecal antibody synthesis of antibodies to Bbsl, which alongside clinical and exposure history can be used to establish a diagnosis of NLD.

**Reference Values**

Negative

Reference values apply to all ages.

**Interpretation**

Negative:

No antibodies to Lyme disease causing *Borrelia* species detected in spinal fluid. A negative result in a patient with appropriate exposure history and symptoms consistent with neuroinvasive Lyme disease should not be used to exclude infection. Testing for antibodies to Lyme disease-causing *Borrelia* species in serum should be performed.

Reactive:

Supplemental testing to determine a Lyme central nervous system antibody index has been ordered. Diagnosis of neuroinvasive Lyme disease should not be established solely based on a reactive screening result.

**Cautions**

A single negative result should not be used to exclude the diagnosis of neuroinvasive Lyme disease in a patient with appropriate exposure history and symptoms suggestive of infection. Testing of serum samples using the CDC recommended standard 2-tiered testing algorithm should be performed (LYME / Lyme Disease Serology, Serum).

False-negative results may be acquired in patients tested soon after infection, prior to the development of a detectable level of antibodies in the spinal fluid.

False-reactive results may occur in patients with syphilis or *Leptospira* infections. Patient management decisions should not be made on a single reactive result.

**Clinical Reference**


**Performance**
Method Description

The test kit contains microtiter strips with break-off reagent wells coated with a mix of Bb sl antigens (whole antigen extracts of *Borrelia burgdorferi* sensu stricto, *B. afzelii*, *B. garinii* and recombinant VlsE of *B. burgdorferi* sensu stricto). In the first reaction step, diluted patient samples are incubated in the wells. In the case of positive samples, *Borrelia*-specific-IgG antibodies will bind to the antigens. To detect the bound antibodies, a second incubation is carried out using an enzyme-labelled antihuman IgG (enzyme conjugate), followed by a third incubation using chromogen/substrate (TMB/H2O2), which catalyzes a color reaction that is then measured for optical density (OD) using spectrophotometry. The obtained OD values of the paired patient serum and spinal fluid samples are compared against a 6-level calibration curve to quantitatively determine the relative anti-*Borrelia* IgG antibody titers. (Package insert: Antibodies of the IgG class against *Borrelia* in cerebrospinal fluid, Euroimmun Ag, Seekamp 31, 23560 Luebeck, Germany 06/15/2015)

PDF Report

No

Day(s) and Time(s) Test Performed

Monday, Wednesday, Friday; 8 a.m.

Analytic Time

Same day/1 day

Maximum Laboratory Time

4 days

Specimen Retention Time

14 days

Performing Laboratory Location

Rochester

Fees and Codes

Fees

- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

86618-Lyme spinal fluid

86618 x 2-Lyme, Serum and spinal fluid if applicable for Antibody Index

82040-Albumin, serum if applicable for Antibody Index

82042-Albumin, spinal fluid if applicable for Antibody Index
82784 x 2-IgG, serum and spinal fluid if applicable for Antibody Index

**LOINC® Information**

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>LNBAB</td>
<td>Lyme CNS Infection IgG w/ AI Reflex</td>
<td>92815-0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Result ID</th>
<th>Test Result Name</th>
<th>Result LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>LNB1</td>
<td>Lyme CNS Infection IgG, CSF</td>
<td>92813-5</td>
</tr>
<tr>
<td>LNBAS</td>
<td>Lyme CNS Infection IgG, S</td>
<td>92814-3</td>
</tr>
<tr>
<td>LNB2</td>
<td>Lyme CNS Infection IgG Interp</td>
<td>69048-7</td>
</tr>
</tbody>
</table>